GT Biopharma, Inc. (the "Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) ...
GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...
Chen et al. construct a comprehensive immune landscape of lymphatic malformations (LMs) atlas at single-cell resolution, uncovering pro-inflammatory responses and immune dysfunction characteristic.
Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s ...
Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...
A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...
Techno-Science.net on MSN
A method to produce anti-cancer killer cells en masse
Natural killer cells, or NK cells, are elements of the immune system capable of rapidly locating and destroying cancerous or infected cells. Their use in therapy, particularly by equipping them ...
The company is restarting its solid tumor program with the Phase I trial after the company paused it to focus on blood cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results